In Brief: Sequus
Executive Summary
Sequus: Final chemistry issue regarding the approval of Doxil liposomal doxorubicin is resolved with FDA Nov. 7, Sequus President Scott Minick tells an Oppenheimer & Co. conference Nov. 8. Doxil labeling for treatment of refractory Kaposi's sarcoma will state that 27%-48% of patients responded to the compound and that Doxil selectively enters KS lesions, leading to greater tumor concentration of doxorubicin than with non-liposomal formulations. Doxil will be priced similarly to Bristol-Myers Squibb's Taxol, Minick said. The Menlo Park, Calif.-based company is ready to launch Doxil immediately upon approval, he added...